Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2007

View Archived Issues

New Integrity Disease Briefing highlights head and neck cancers

Preclinical and phase I data on activity of AT-1001 presented

Satraplatin improves pain and PSA responses in phase III trial

Vardenafil studies presented at European Association of Urology congress

LY-2076962, non-morphinan opioid receptor antagonist, evaluated in phase I study

Celsion files for SPA for ThermoDox

MEDI-545 begins clinical evaluation in psoriasis

Novartis signs agreement for branded interferon beta-1b

New therapeutic agents for thrombotic disorders disclosed in recent patent literature

Ethics approval for second phase IIa neuropathic pain study of ACV-1

EvoGenix achieves milestone in GSK collaboration for protein-based therapeutics

Zanaflu registered as brand name for chitosan gel

Recent patents report novel analgesic agents

CHR-2797 begins phase II for AML in elderly patients

Semafore's PI3K inhibitor studied in phase I for solid tumors

Arrowhead Research forms new nanomedicine subsidiary

New agents for treating neurological disorders disclosed in recent patents

Merck & Co. and Schering-Plough to develop new cholesterol lowering product

PF-184298 presented as clinical candidate by Pfizer

Phase III study of vilazodone in depression completes enrollment

European orphan drug designation for enzastaurin in DLBCL

orBec cleared for phase II study in prevention of GVHD

New selective androgen receptor modulator profiled at Merck

BioLineRx in-licenses new therapeutic candidates

Positive phase IIa results for DIO-902 in type 2 diabetes

Cephalon files for European approval of fentanyl effervescent buccal tablet

Modiodal launched in Japan

AZ-004 reduces agitation in schizophrenic patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...